Rockwell Medical (NASDAQ:RMTI) and Magna-Lab (OTCMKTS:MAGAA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Risk and Volatility
Rockwell Medical has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Magna-Lab has a beta of 8.87, meaning that its share price is 787% more volatile than the S&P 500.
Valuation and Earnings
This table compares Rockwell Medical and Magna-Lab’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Rockwell Medical||$63.39 million||2.74||-$32.13 million||($0.47)||-6.43|
Magna-Lab has lower revenue, but higher earnings than Rockwell Medical.
This is a breakdown of recent recommendations and price targets for Rockwell Medical and Magna-Lab, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Rockwell Medical currently has a consensus price target of $11.00, suggesting a potential upside of 264.24%. Given Rockwell Medical’s higher probable upside, equities research analysts clearly believe Rockwell Medical is more favorable than Magna-Lab.
Institutional & Insider Ownership
19.9% of Rockwell Medical shares are held by institutional investors. 3.9% of Rockwell Medical shares are held by insiders. Comparatively, 15.3% of Magna-Lab shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares Rockwell Medical and Magna-Lab’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Rockwell Medical Company Profile
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis. It is also developing an intravenous formulation of Triferic for use by hemodialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. Its target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1994 and is based in Wixom, Michigan.
Magna-Lab Company Profile
Magna-Lab, Inc. is a shell company, which intends to identify and merge with an operating company. The company was founded by Lawrence A. Minkoff on February 22, 1991 and is headquartered in Syosset, NY.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.